Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study
Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study
复制标题
DOI：
10.1007/s11307-021-01679-w
复制
发表时间：
2021-11-23
影响因子：
3.1
通讯作者：
Wang, Xinlu
中科院分区：
文献类型：
--
作者：
Li, Youcai;Lin, Xinqing;Wang, Xinlu
本研究的目的是比较F-18标记成纤维细胞激活蛋白抑制剂（[F-18]F-FAPI）与F-18标记氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（[F-18]F-FDG PET/CT）在肺腺癌（LAD）患者中的初步分期。我们前瞻性地分析了2020年5月至2021年8月期间接受[F-18]F-FAPI和[F-18]F-FDG PET/CT检查的LAD患者的图像。使用配对样本t检验比较[F-18]F-FAPI和[F-18]F-FDG的摄入量，使用Wilcoxon符号秩检验比较病变数量。结果对34例LAD患者进行了评估。患者在原发病变中表现出高[F-18]F-FAPI摄取（SUVmax 12.54 +/- 3.77）。[F-18]F-FAPI和[F-18]F-FDG对原发肿瘤的检出率均为100%。然而，[F-18]F-FAPI在淋巴结、胸膜、骨骼和其他组织病变中的SUVmax高于[F-18]F-FDG(均为P
Purpose The purpose of this study was to compare the primary staging of F-18 labeled fibroblast activation protein inhibitor ([F-18]F-FAPI) with that of F-18 labeled fluordesoxyglucose positron emission tomography/computed tomography ([F-18]F-FDG PET/CT) in patients with lung adenocarcinoma (LAD). Procedures We prospectively analyzed the images of LAD patients who underwent [F-18]F-FAPI and [F-18]F-FDG PET/CT between May 2020 and August 2021. [F-18]F-FAPI and [F-18]F-FDG uptakes were compared using the paired samples t test, and lesion numbers were compared using the Wilcoxon signed-rank test. Results Thirty-four LAD patients were evaluated. Patients showed high [F-18]F-FAPI uptake in primary lesions (SUVmax 12.54 +/- 3.77). Both [F-18]F-FAPI and [F-18]F-FDG had 100% detection rates for primary tumors. However, [F-18]F-FAPI showed higher SUVmax than [F-18]F-FDG in lesions of the lymph nodes, pleura, bones, and other tissues (all P